Matches in Wikidata for { <http://www.wikidata.org/entity/Q61937084> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q61937084 description "assaig clínic" @default.
- Q61937084 description "clinical trial" @default.
- Q61937084 description "clinical trial" @default.
- Q61937084 description "clinical trial" @default.
- Q61937084 description "clinical trial" @default.
- Q61937084 description "ensaio clínico" @default.
- Q61937084 description "ensayo clínico" @default.
- Q61937084 description "ensayu clínicu" @default.
- Q61937084 description "essai clinique" @default.
- Q61937084 description "klinisch onderzoek" @default.
- Q61937084 description "клінічне випробування" @default.
- Q61937084 description "կլինիկական փորձարկում" @default.
- Q61937084 description "临床试验" @default.
- Q61937084 name "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer" @default.
- Q61937084 type Item @default.
- Q61937084 label "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer" @default.
- Q61937084 prefLabel "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer" @default.
- Q61937084 P1050 Q61937084-B7E7DC12-267A-4D28-A72F-7663FC8D0BA9 @default.
- Q61937084 P1132 Q61937084-67820460-301C-4D5B-B5BB-EC7D857D479C @default.
- Q61937084 P1476 Q61937084-0D6D00F1-5ABC-4AAB-BE4C-7A01CA4F4CFF @default.
- Q61937084 P17 Q61937084-CD61B631-F7DC-4395-9EF0-8363421D3931 @default.
- Q61937084 P2899 Q61937084-0E651EC3-4DA5-4AB1-9C79-3EC7DD6F3542 @default.
- Q61937084 P3098 Q61937084-EB1F294B-D9B1-4CAB-B0BF-1DD952EAF192 @default.
- Q61937084 P31 Q61937084-DF618089-41C3-4D6C-869C-A3DDCB4C37E1 @default.
- Q61937084 P4844 Q61937084-2EDAE653-A70A-49A2-99C1-EB26C21A60AD @default.
- Q61937084 P580 Q61937084-EC0BDD49-3F19-4248-853C-8AED6EE933F8 @default.
- Q61937084 P582 Q61937084-502AAC1C-7CAB-45CA-B0FC-B12EBEE4BF30 @default.
- Q61937084 P6099 Q61937084-86AFEA95-C0CC-469F-825B-F93BD2ECB341 @default.
- Q61937084 P8005 Q61937084-909B716C-1E4D-41A8-A464-82C8536C9191 @default.
- Q61937084 P8363 Q61937084-711E926A-787C-4237-9376-6F9786FF68CD @default.
- Q61937084 P1050 Q33525 @default.
- Q61937084 P1132 "+191" @default.
- Q61937084 P1476 "Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer" @default.
- Q61937084 P17 Q30 @default.
- Q61937084 P2899 "+18" @default.
- Q61937084 P3098 "NCT01091428" @default.
- Q61937084 P31 Q30612 @default.
- Q61937084 P4844 Q423762 @default.
- Q61937084 P580 "2010-04-16T00:00:00Z" @default.
- Q61937084 P582 "2014-08-12T00:00:00Z" @default.
- Q61937084 P6099 Q42824440 @default.
- Q61937084 P8005 Q76651189 @default.
- Q61937084 P8363 Q78089383 @default.